Related Experiment Video
Updated: Sep 25, 2026
The bm12 Inducible Model of Systemic Lupus Erythematosus (SLE) in C57BL/6 Mice
Published on: November 1, 2015
BMS-214662 (Bristol-Myers Squibb)
1Department of Medicine (Breast Unit), Royal Marsden Hospital, Fulham Road, London, SW3 6JJ, UK. stephen@icr.ac.uk
Abstract:
Bristol-Myers Squibb is developing BMS-214662, a farnesyl transferase inhibitor, for the potential treatment of cancer. By October 2000, preclinical investigations were ongoing in Japan. By February 2001, the drug was in phase II trials in the US for pancreatic, head and neck, lung and colorectal cancers.
Insights
Bristol-Myers Squibb is investigating BMS-214662, a farnesyl transferase inhibitor, as a potential cancer treatment. Clinical trials are underway in the US for various cancers, including pancreatic and lung.
Area of Science:
- Oncology
- Pharmacology
Background:
- Bristol-Myers Squibb is developing BMS-214662.
- BMS-214662 is a farnesyl transferase inhibitor.
Purpose of the Study:
- To evaluate the potential of BMS-214662 in cancer treatment.
Main Methods:
- Preclinical investigations were conducted in Japan.
- Phase II clinical trials initiated in the US.
Main Results:
- BMS-214662 is under investigation for multiple cancer types.
Conclusions:
- BMS-214662 shows potential as a novel cancer therapeutic agent.
